Document is current
Any future updates will be listed below
-
Authors
Ma, Xiang-Yu
Qi, Cheng-yu
Xu, Xing-yi
Li, Hui
Liu, Chang-Dong
Wen, Xiang-Ru
Fu, Yan-Yan
Liu, Yan
Liang, Jia
Huang, Cheng-Yu
Li, Dan-Dan
Li, Yan
Shen, Qian-Cheng
Qi, Qian-Zhi
Zhu, Guang
Wang, Nan
Zhou, Xiao-Yan
Song, Yuan-Jian
-
Funding
Funding for this research was provided by:
the Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates (202210313055Z)
the National Natural Science Foundation of China (82271205, 82271356)
Jiangsu Provincial Science and Technology Program Key R&D Projects (BE2022713)
China International Medical Exchange Foundation Cerebrovascular Disease Youth Innovation Fund Program (Z-2016-20-2101-11)
- License Information
-
More Information
Article History
Received: 13 January 2024
Accepted: 14 May 2024
First Online: 23 May 2024
Declarations
:
: The project “PRDX1 peptide attenuates ischemic brain injury through inhibition of TLR4/NF-κB signaling pathway” was examined and verified by the Laboratory Animal Ethics Committee of Xuzhou Medical University in accordance with the Guide to Laboratory Animal Ethics Examination of Xuzhou Medical University (202211S030). The related animal experiments were permitted.
: Not applicable.
: The authors declare no competing interests.
